The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent

References

• PirmohamedMBackDJThe pharmacogenomics of HIV therapyPharmacogenomics J20011424325311908767
   PubMedGoogle Scholar
• KayserSPharmacogenomics and the potential for personalized therapeutics in cardiovascular diseaseProg Cardiovasc Nurs200722210410717541322
   PubMedGoogle Scholar
• HaasDWRibaudoHJKimRBPharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group studyAIDS200418182391240015622315
   PubMed Web of Science ®Google Scholar
• HammerSMEronJJJrReissPInternational AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelJAMA2008300555557018677028
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338138538609516219
   PubMed Web of Science ®Google Scholar
• KilmarxPHGlobal epidemiology of HIVCurr Opin HIV AIDS20094424024619532059
   PubMed Web of Science ®Google Scholar
• GarberMHIV-infected African Americans are willing to participate in HIV treatment trialsJ Gen Intern Med2007221174217351837
   PubMed Web of Science ®Google Scholar
• BurroughsVJMaxeyRWLevyRARacial and ethnic differences in response to medicines: towards individualized pharmaceutical treatmentJ Natl Med Assoc20029410 Suppl12612401060
   PubMed Web of Science ®Google Scholar
• Rodríguez-NóvoaSBarreiroPJiménez-NacherIRendónASorianoVPharmacogenetics in HIV therapyAIDS Rev20057210311216092504
   PubMed Web of Science ®Google Scholar
• PourpakZFazlollahiMRFattahiFUnderstanding adverse drug reactions and drug allergies: principles, diagnosis and treatment aspectsRecent Pat Inflamm Allergy Drug Discov200821244619075990
   PubMedGoogle Scholar
• TrowsdaleJCampbellRDComplexity in the major histocompatibility complexEur J Immunogenet1992191–245551567814
   PubMedGoogle Scholar
• SaagMBaluRPhillipsEStudy of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study TeamHigh sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsClin Infect Dis2008461111111818444831
   PubMed Web of Science ®Google Scholar
• MallalSPhillipsECarosiGHLA-B*5701 screening for hypersensitivity to abacavirN Engl J Med200835856857918256392
   PubMed Web of Science ®Google Scholar
• HetheringtonSHughesARMostellerMGenetic variations in HLA-B region and hypersensitivity reactions to abacavirLancet20023591121112211943262
   PubMed Web of Science ®Google Scholar
• HughesARMostellerMBansalATCNA30027 Study TeamCNA30032 Study TeamAssociation of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsPharmacogenomics20045220321115016610
   PubMed Web of Science ®Google Scholar
• CresseyTRLallemantMPharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an updateInfect Genet Evol20077233334217045554
   PubMed Web of Science ®Google Scholar
• RauchANolanDMartinAProspecitve genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyClin Infect Dis20064319910216758424
   PubMed Web of Science ®Google Scholar
• MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet2002359930872773211888582
   PubMed Web of Science ®Google Scholar
• LallemantMJLe CoeurGMarySSingle-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in ThailandN Engl J Med2004351321722815247338
   PubMed Web of Science ®Google Scholar
• ZhouSFStructure, function and regulation of P-glycoprotein and its clinical relevance in drug dispositionXenobiotica2008387–880283218668431
   PubMed Web of Science ®Google Scholar
• CuppMJTracyTSCytochrome P450: new nomenclature and clinical implicationsAm Fam Physician19985711071169447218
   PubMed Web of Science ®Google Scholar
• EndeMSahtoeCDielemanJBurgerDSchaikRPrevalence of single nucleotide polymorphisms in MDR-1 and CYP3 A genes within a heterogenous HIV-1-infected population and effect on nevirapine plasma levelsSan Francisco, CAConference on Retroviruses and Opportunistic Infections2004
   Google Scholar
• HaasDWBartlettJAAndersenJWAdult AIDS Clinical Trials GroupPharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaborationClin Infect Dis200643678378616912957
   PubMed Web of Science ®Google Scholar
• RitchieMDHaasDWMotsingerAADrug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicityClin Inf Dis200643779782
   PubMed Web of Science ®Google Scholar
• HaasDWSmeatonLMShaferRWPharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyJ Infect Dis20051921931194216267764
   PubMed Web of Science ®Google Scholar
• SaitohAFletcherCVBrundageREfavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphismJ Acquir Immune Defic Syndr200745328028517356468
   PubMed Web of Science ®Google Scholar
• RibaudoHJHaasDWTierneyCAdult AIDS Clinical Trials Group StudyPharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyClin Infect Dis200642340140716392089
   PubMed Web of Science ®Google Scholar
• Friis-MøllerNWeberRReissPDAD study groupCardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS2003171179119312819520
   PubMed Web of Science ®Google Scholar
• d’ArminioASabinCAPhillipsANCardio- and cerebrovascular events in HIV-infected personsAIDS2004181811181715316342
   PubMed Web of Science ®Google Scholar
• Mary-KrauseMCotteLSimonAPartisaniMCostagliolaDIncreased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menAIDS2003172479248614600519
   PubMed Web of Science ®Google Scholar
• FontasEvan LethFSabinCALipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?J Infect Dis20041891056107414999610
   PubMed Web of Science ®Google Scholar
• HuiDYEffects of HIV protease inhibitor therapy on lipid metabolismProg Lipid Res200342819212547652
   PubMed Web of Science ®Google Scholar
• GrinspoonSCarrACardiovascular risk and body-fat abnormalities in HIV-infected adultsN Engl J Med2005352486215635112
   PubMed Web of Science ®Google Scholar
• BonnetERuidavetsJBTuechJApoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophyJ Clin Endocrinol Metab20018629630211232015
   PubMed Web of Science ®Google Scholar
• CahnPEGatellJMSquiresKAtazanavir – a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trialsJ Int Assoc Physicians AIDS Care (Chic Ill)200439298
   PubMedGoogle Scholar
• LiangJSDistlerOCooperDAHIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemiaNat Med200171327133111726973
   PubMed Web of Science ®Google Scholar
• PuroVEffect of short-course of antiretroviral agents on serum triglycerides of healthy individualsAIDS2000142407240811089633
   PubMed Web of Science ®Google Scholar
• OlsonREDiscovery of the lipoproteins, their role in fat transport and their significance as risk factorsJ Nutr19981282 Suppl439S443S9478044
   PubMed Web of Science ®Google Scholar
• SegrestJPJonesMKDe LoofHDashtiNStructure of Apolipoprotein B-100 in low denstiy lipoproteinsJ Lipid Res20014291346136711518754
   PubMed Web of Science ®Google Scholar
• SurguchovAPPageGPSmithLPatschWBoerwinkleEPolymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemiaArterioscler Thromb Vasc Biol1996169419478696957
   PubMed Web of Science ®Google Scholar
• LiWWDammermanMMSmithJDMetzgerSBreslowJLLeffTCommon genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemiaJ Clin Invest199596260126058675624
   PubMed Web of Science ®Google Scholar
• DammermanMSandkuijlLAHalaasJLChungWBreslowJLAn apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3’ untranslated region polymorphismsProc Natl Acad Sci U S A199390456245668099442
   PubMed Web of Science ®Google Scholar
• van DijkKWRensenPCVosholPJHavekesLMThe role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?Curr Opin Lipidol20041523924615166778
   PubMed Web of Science ®Google Scholar
• Dallinga-ThieGMvan Linde-Sibenius TripMRotterJIComplex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypesJ Clin Invest1997999539619062353
   PubMed Web of Science ®Google Scholar
• MahleyRWRallSCJrApolipoprotein E: far more than a lipid transport proteinAnnu Rev Genomics Hum Genet2000150753711701639
   PubMed Web of Science ®Google Scholar
• TarrPETaffePBleiberGModeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy associated lipid disordersJ Infect Dis20051911419142615809899
   PubMed Web of Science ®Google Scholar
• FauvelJBRuidavetsEFerrieresJBAn interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patientsAIDS200115182397240611740190
   PubMed Web of Science ®Google Scholar
• GardnerCDWinklebyMAFortmannSPPopulation frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988–1994)Am J Cardiol20008629930410922437
   PubMed Web of Science ®Google Scholar
• FoulkesASWohlDAFrankIAssociations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapyPLoS Med200632e5216417409
   PubMed Web of Science ®Google Scholar